USPTO serial 79067099
SPHEROTEC
Reviewed by CopyMark Law Group
Reg. 4434280Status 404
- Filing date
- Status date
- Registration date
- Nov 19, 2013
- Examiner
- MITTLER, KEVIN A
- Law office
- PUBLICATION AND ISSUE SECTION
What this means
This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.
Need help with SPHEROTEC?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Jeffrey A. Smith
JEFFREY A SMITH MILLEN WHITE ZELANO & BRANIGAN PC2200 CLARENDON BLVDSUITE 1400ARLINGTON, VA 22201-3360Goods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 001 | Scaffold-free and solid phase free chemical and chemical preparations used in tissue and cell-based spheroid cultures for scientific purposes; chemical preparations, namely, collections of biological tissues and cells for scientific purposes; tissue in the nature of biological tissue, namely, blood, stem cells, tumour cells, fibroblasts, foam cells, glial cells, adipocytes, benign and malignant primary cells, hybridomas, antibody producing cells; arrays of biological cells, namely, cancer cells, benign cells, stem cells, tumour cells, fibroblasts, foam cells, glial cells, adipocytes, benign and malignant primary cells, hybridomas, antibody producing cells; fixed arrays of biological cells, namely, cancer cells, benign cells, stem cells, tumour cells, fibroblasts, foam cells, glial cells, adipocytes, benign and malignant primary cells, hybridomas, antibody producing cells; biological cells prepared into a format for scientific purposes and research for scientific research use; cell culture systems, three-dimensional cell culture system comprising cell clusters and aggregates for scientific research use | SECTION 70 - CANCELLED | — |
| 005 | Scaffold-free or solid phase free pharmaceutical and veterinary preparations used in tissue and cell-based spheroid cultures for the diagnosis and treatment of cancer; collection of biological tissue and cells, namely, surgical tissues and cells intended for the generation of cell clusters and cell aggregates for medical purposes; tissue, namely, surgical tissues, for diagnosis and treatment of cancer and for medical purposes; fibroblasts, foam cells, glial cells, stem cells, adipocytes, benign and malignant primary cells, hybridomas, antibody producing cells for the generation of cell clusters or cell aggregates | SECTION 70 - CANCELLED | — |
| 035 | Compilation and management of computerized databases used for tissue and cell-based spheroid cultures | SECTION 70 - CANCELLED | — |
| 042 | Scientific and technological services and research and design in the field of integrated system architecture that allows for the rapid development of highly interactive and customizable learning applications; computer diagnostic services; diagnostic testing of humans for medical research purposes; medical research services; medical research in the field of oncology; medical research in the field of disease indications and identification of tumor indications; testing of drugs, biological and chemical preparations for medical research purposes; pharmaceutical research, inspection and development; pharmaceutical drug development services; medical and scientific research, namely, conducting clinical trials concerning biological and chemical preparations and pharmaceuticals; medical and scientific research, namely, researching profiles of biological and chemical preparations, pharmaceuticals, antigens; testing for scientific and medical research purposes of combinations of biological and chemical preparations and pharmaceuticals; testing for medical research purposes to determine the chemo-resistance and chemo-sensitivity of biological and chemical preparations and pharmaceuticals; medical research in the nature of testing the efficacy and toxicity of biological and chemical preparations and pharmaceuticals; medical research in the nature of testing the effects of biological and chemical preparations and pharmaceuticals on cell toxicity levels; medical research in the nature of pharmacokinetic testing of biological and chemical substances and known pharmaceuticals; medical research concerning the absorption, delivery, metabolism, excretion and toxicity testing of biological and chemical preparations and pharmaceuticals ; medical and scientific research in the field of pharmaceuticals, genetic changes induced by biological or chemical preparations or pharmaceuticals, and pharmaceutical dosing levels; research and development of pharmaceutical treatment therapies for others; scientific research concerning tumour biology, progression and metastasis; medical research concerning optimal treatment and therapy regimes for individuals; medical research concerning optimal cancer therapy for individuals; research and development of new products for others in relation to prediction of cancer therapy; scientific and medical research in the field of radiotherapy; research, development and design of new radiotherapy products for others; scientific and medical research in the field of radiochemotherapy; research, development and design of new products for others in the field of radiochemotherapy; scientific and medical research in the field of stem cells and biomarker discovery, characterization and development; medical research in the fields of ex-vivo therapies, patient material profiling, tumor profiling, in vitro modeling of tissue and biological systems, cell culture systems, three-dimensional cell culture systems, and three-dimensional culture of donor and patient cells; laboratory research services, namely, isolation, culture and treatment of donor and patient tissues and cells for medical research purposes; research laboratory services, namely, preparation of cell lines, primary tissues and fluids, and biological material into a format for scientific and medical research purposes; medical research concerning immunohistology, immunohistology preparation and investigation;Opposition No. 912064346research laboratory services, namely, creation and preparation of biological material into or onto a format for immunohistology investigation, creation and preparation of biological material on a solid or wax support, preparation of sections or slices of biological material on to slides, all for medical research purposes; medical research concerning small molecule development, preparation and generation, antibody research, development, preparation and generation, and vaccine research, development, preparation and generation; provision of information and data relating to scientific and technological research and development; provision of information and data relating to medical and veterinary research and development; provision of information and data relating to scientific and medical research concerning pharmaceuticals, drug testing, drug discovery and development, and testing of biological material; all of the aforementioned services relating to or using tissue and cell-based spheroids cultures | SECTION 70 - CANCELLED | — |
| 044 | Medical and veterinary services; medical diagnostic testing services; medical diagnostic testing services of humans; medical diagnostic and clinical testing services; medical and clinical oncology diagnostic testing services for humans; medical diagnostic testing services in the field of oncology; performing diagnosis of disease indications, performing diagnosis of tumour disease indications; medical screening services for drugs, biological and chemical entities and potential and known pharmaceuticals; medical services, namely, medical testing for and identifying antigens and providing drug therapy for inhibiting antigens; providing individualizing cancer therapy services; providing medical diagnostic services for cancer therapy; medical services, namely, personalized cancer therapy; medical services, namely, radiotherapy; medical services, namely, radiochemotherapy; medical services, namely, preparations of ex-vivo therapies; all relating to medical and veterinary fields; all of the aforementioned services relating to or using tissue and cell-based spheroids cultures | SECTION 70 - CANCELLED | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by SpheroTec GmbH
- Other trademarks owned by SpheroTec GmbH
- Other trademarks owned by SpheroTec GmbH
- Other trademarks in Class 001
- Other trademarks in Class 005
- Other trademarks in Class 035
- Other trademarks in Class 042
- Other trademarks in Class 044
- Similar marks named SPHEROTEC
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| May 24, 2019 | DENC | NOTIFICATION OF EFFECT OF CANCELLATION OF INTL REG E-MAILED | — |
| May 24, 2019 | DETH | DEATH OF INTERNATIONAL REGISTRATION | — |
| Nov 19, 2018 | REM3 | COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED | — |
| Mar 6, 2014 | FINO | FINAL DECISION TRANSACTION PROCESSED BY IB | — |
| Feb 19, 2014 | FICS | FINAL DISPOSITION NOTICE SENT TO IB | — |
| Feb 19, 2014 | FIMP | FINAL DISPOSITION PROCESSED | — |
| Feb 19, 2014 | FICR | FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB | — |
| Nov 19, 2013 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Oct 16, 2013 | TMBN | TTAB RELEASE CASE TO TRADEMARKS | — |
| Oct 16, 2013 | OP.T | OPPOSITION TERMINATED NO. 999999 | — |
| Oct 16, 2013 | OP.D | OPPOSITION DISMISSED NO. 999999 | — |
| Sep 23, 2013 | PAPER RECEIVED | — | |
| Feb 8, 2013 | DOCK | ASSIGNED TO EXAMINER | — |
| Sep 8, 2012 | RFNP | REFUSAL PROCESSED BY IB | — |
| Aug 7, 2012 | OP.I | OPPOSITION INSTITUTED NO. 999999 | — |
| Aug 6, 2012 | OPNS | OPPOSITION NOTICE (IB REFUSAL) SENT TO IB | — |
| Aug 4, 2012 | OPNC | OPPOSITION NOTICE (IB REFUSAL) CREATED | — |
| Feb 23, 2012 | ETOF | EXTENSION OF TIME TO OPPOSE RECEIVED | — |
| Feb 7, 2012 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Feb 3, 2012 | OPNX | NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB | — |
| Jan 26, 2012 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| Jan 18, 2012 | OPNS | NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB | — |
| Jan 18, 2012 | OP2R | NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB | — |
| Jan 18, 2012 | NPUB | NOTICE OF PUBLICATION | — |
| Jan 3, 2012 | CNEA | EXAMINERS AMENDMENT MAILED | — |
| Dec 31, 2011 | PREV | LAW OFFICE PUBLICATION REVIEW COMPLETED | — |
| Dec 30, 2011 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Dec 30, 2011 | XAEC | EXAMINER'S AMENDMENT ENTERED | — |
| Dec 30, 2011 | CNEA | EXAMINERS AMENDMENT -WRITTEN | — |
| Dec 30, 2011 | ZZZX | PREVIOUS ALLOWANCE COUNT WITHDRAWN | — |
| Nov 22, 2011 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Oct 18, 2011 | RCCK | SUSPENSION CHECKED - TO ATTORNEY FOR ACTION | — |
| Apr 18, 2011 | RCSC | REPORT COMPLETED SUSPENSION CHECK CASE STILL SUSPENDED | — |
| Oct 18, 2010 | RCSC | REPORT COMPLETED SUSPENSION CHECK CASE STILL SUSPENDED | — |
| Oct 9, 2010 | OPNX | NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB | — |
| Sep 23, 2010 | OPNS | NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB | — |
| Sep 23, 2010 | OPNR | NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB | — |
| Apr 16, 2010 | RCSC | REPORT COMPLETED SUSPENSION CHECK CASE STILL SUSPENDED | — |
| Apr 16, 2010 | ALIE | ASSIGNED TO LIE | — |
| Oct 16, 2009 | CNSL | LETTER OF SUSPENSION MAILED | — |
| Oct 15, 2009 | CNSL | SUSPENSION LETTER WRITTEN | — |
| Sep 28, 2009 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Sep 28, 2009 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Sep 28, 2009 | ALIE | ASSIGNED TO LIE | — |
| Sep 24, 2009 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Sep 23, 2009 | ARAA | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Sep 23, 2009 | REAP | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | — |
| Jun 5, 2009 | RFNT | REFUSAL PROCESSED BY IB | — |
| May 11, 2009 | RFCS | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB | — |
| May 11, 2009 | RFRR | REFUSAL PROCESSED BY MPU | — |
| May 9, 2009 | RFCR | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW | — |
| May 8, 2009 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Apr 28, 2009 | MAFR | APPLICATION FILING RECEIPT MAILED | — |
| Apr 24, 2009 | DOCK | ASSIGNED TO EXAMINER | — |
| Apr 24, 2009 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Apr 23, 2009 | REPR | SN ASSIGNED FOR SECT 66A APPL FROM IB | — |